2024
Buprenorphine for Opioid Use Disorder—An Essential Medical Treatment
Weimer M, Morford K. Buprenorphine for Opioid Use Disorder—An Essential Medical Treatment. JAMA Internal Medicine 2024, 184: 1248-1249. PMID: 39186298, DOI: 10.1001/jamainternmed.2024.3977.Peer-Reviewed Original ResearchLBA9 Clinical insights from ultra-sensitive tumour-informed ctDNA tracking across the TRACERx cohort
Black J, Karasaki T, Abbott C, Boyle S, Li B, Al Bakir M, Liu W, Veeriah S, Jamal-Hanjani M, McGranahan N, Frankell A, Chen R, Swanton C. LBA9 Clinical insights from ultra-sensitive tumour-informed ctDNA tracking across the TRACERx cohort. Annals Of Oncology 2024, 35: s1203. DOI: 10.1016/j.annonc.2024.08.2246.Peer-Reviewed Original ResearchClinical insightsComparative Study of the Efficacy and Side Effects of Brand-Name and Generic Clozapine for Long-Term Maintenance Treatment Among Korean Patients With Schizophrenia: A Retrospective Naturalistic Mirror-Image Study
Kang N, Yoon H, Kim H, Jeong J, Kim M, Kwon J. Comparative Study of the Efficacy and Side Effects of Brand-Name and Generic Clozapine for Long-Term Maintenance Treatment Among Korean Patients With Schizophrenia: A Retrospective Naturalistic Mirror-Image Study. Psychiatry Investigation 2024, 21: 311-320. PMID: 38569589, PMCID: PMC10990625, DOI: 10.30773/pi.2023.0413.Peer-Reviewed Original ResearchMirror-image studyMaintenance treatmentTreatment-resistant schizophreniaFormulation of clozapineLong-term maintenance treatmentConcentration-to-dose ratioClozapine useGeneric clozapineClozapineClozarilPsychiatric hospitalNo significant differenceSchizophreniaKorean patientsMedical records of patientsClinical insightsBlood test findingsElectronic medical records of patientsSignificant differenceRecords of patientsBrand-name formulationConcomitant medicationsCo-medicationHospitalization durationLaboratory findingsDo metacognitive therapies for schizophrenia-spectrum disorders work? A meta-analytic investigation.
Melville G, Hoffman M, Pollock A, Kurtz M. Do metacognitive therapies for schizophrenia-spectrum disorders work? A meta-analytic investigation. Psychological Medicine 2024, 54: 1510-1518. PMID: 38509837, DOI: 10.1017/s0033291724000564.Peer-Reviewed Original ResearchSchizophrenia spectrum disordersMetacognitive therapyNegative symptomsSocial cognitionEfficacy of metacognitive therapyMeta-cognitive therapySingle-session interventionSmall-to-moderate effectsDuration of illnessAntipsychotic dosagePositive symptom outcomesPositive symptomsIllness insightPotential moderatorsPsychosocial functioningSymptom outcomesCognitive biasesSecondary symptomsControlled trialsClinical insightsSample differencesCognitionSmall effectsSymptomsDisordersSynaptic loss and its association with symptom severity in Parkinson’s disease
Holmes S, Honhar P, Tinaz S, Naganawa M, Hilmer A, Gallezot J, Dias M, Yang Y, Toyonaga T, Esterlis I, Mecca A, Van Dyck C, Henry S, Ropchan J, Nabulsi N, Louis E, Comley R, Finnema S, Carson R, Matuskey D. Synaptic loss and its association with symptom severity in Parkinson’s disease. Npj Parkinson's Disease 2024, 10: 42. PMID: 38402233, PMCID: PMC10894197, DOI: 10.1038/s41531-024-00655-9.Peer-Reviewed Original ResearchSynaptic density lossPositron emission tomographyBinds to synaptic vesicle glycoprotein 2AAssociated with symptom severityParkinson's diseaseHigh-resolution positron emission tomographySynaptic vesicle glycoprotein 2ADuration of illnessPositron emission tomography scanBrain perfusionIllness durationSymptom severitySeverity of symptomsHC groupSubstantia nigraSynaptic densityLiving brainPD individualsClinical insightsDensity lossPD patientsEmission tomographyBrainSynaptic lossSynapse lossAnesthesia for Rare Fetal and Placental Conditions
Ferschl M, Rollins M. Anesthesia for Rare Fetal and Placental Conditions. 2024, 456-468. DOI: 10.1017/9781009070256.029.Peer-Reviewed Original ResearchManagement of pregnant womenObstetric care providersObstetric anesthesiologistPlacental conditionsObstetric anesthetistsRare inherited conditionsPregnant womenRare conditionCare providersCase reportManagement guidelinesSubstance abuseRevised third editionClinical insightsAnesthesiaVisual aidsThird EditionTeam of editorsPerinatologistsFetalCaregivers
2021
CD74 is a regulator of hematopoietic stem cell maintenance
Becker-Herman S, Rozenberg M, Hillel-Karniel C, Gil-Yarom N, Kramer M, Barak A, Sever L, David K, Radomir L, Lewinsky H, Levi M, Friedlander G, Bucala R, Peled A, Shachar I. CD74 is a regulator of hematopoietic stem cell maintenance. PLOS Biology 2021, 19: e3001121. PMID: 33661886, PMCID: PMC7963458, DOI: 10.1371/journal.pbio.3001121.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnimalsAntigens, Differentiation, B-LymphocyteBone Marrow CellsBone Marrow TransplantationCell LineageFemaleHealthy VolunteersHematopoietic Stem CellsHistocompatibility Antigens Class IIHumansIntramolecular OxidoreductasesMacrophage Migration-Inhibitory FactorsMaleMiceMice, Inbred C57BLSignal TransductionConceptsMacrophage migration inhibitory factorHematopoietic stem cellsBone marrowCytokine macrophage migration inhibitory factorMigration inhibitory factorNumber of HSPCsTransplant protocolsCD18 expressionClinical transplantationInduced SurvivalCD74Inhibitory factorBM nicheCell surface receptorsSelf-renewal propertiesClinical insightsProgenitor cellsBlood cell lineagesSurface receptorsStem cellsHematopoietic stemCell lineagesCellsUndifferentiated cellsHematopoietic stem cell maintenance
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply